251 related items for PubMed ID: 26353031
1. Patterns of Fever in Children After Primary Treatment for Kawasaki Disease.
Jaggi P, Wang W, Dvorchik I, Printz B, Berry E, Kovalchin JP, Texter K, Ramilo O, Burns JC, Tremoulet AH.
Pediatr Infect Dis J; 2015 Dec; 34(12):1315-8. PubMed ID: 26353031
[Abstract] [Full Text] [Related]
2. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
Miyata K, Bainto EV, Sun X, Jain S, Dummer KB, Burns JC, Tremoulet AH.
Arch Dis Child; 2023 Oct; 108(10):833-838. PubMed ID: 37258054
[Abstract] [Full Text] [Related]
3. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC, KIDCARE Multicenter Study Group, Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S.
Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
[Abstract] [Full Text] [Related]
4. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S, KIDCARE Multicenter Study Group.
Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
[Abstract] [Full Text] [Related]
5. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
Iio K, Morikawa Y, Miyata K, Kaneko T, Misawa M, Yamagishi H, Miura M.
J Pediatr; 2022 Jan; 240():158-163.e4. PubMed ID: 34461064
[Abstract] [Full Text] [Related]
6. Correlation of Coronary Artery Abnormalities with Fever Pattern in Patients with Kawasaki Disease.
Tanaka A, Inoue M, Hoshina T, Koga H.
J Pediatr; 2021 Sep; 236():95-100. PubMed ID: 34019881
[Abstract] [Full Text] [Related]
7. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[Abstract] [Full Text] [Related]
8. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
9. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis.
Dionne A, Burns JC, Dahdah N, Tremoulet AH, Gauvreau K, de Ferranti SD, Baker AL, Son MB, Gould P, Fournier A, Newburger JW, Friedman KG.
Pediatrics; 2019 Jun; 143(6):. PubMed ID: 31048414
[Abstract] [Full Text] [Related]
10. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[Abstract] [Full Text] [Related]
11. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis.
Friedman KG, Gauvreau K, Baker A, Son MB, Sundel R, Dionne A, Giorgio T, De Ferranti S, Newburger JW.
Arch Dis Child; 2021 Mar; 106(3):247-252. PubMed ID: 32943389
[Abstract] [Full Text] [Related]
12. Targeted Use of Prednisolone with Intravenous Immunoglobulin for Kawasaki Disease.
Sakai H, Iwashima S, Sano S, Akiyama N, Nagata E, Harazaki M, Fukuoka T.
Clin Drug Investig; 2021 Jan; 41(1):77-88. PubMed ID: 33341911
[Abstract] [Full Text] [Related]
13. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
Friedman KG, Gauvreau K, Hamaoka-Okamoto A, Tang A, Berry E, Tremoulet AH, Mahavadi VS, Baker A, deFerranti SD, Fulton DR, Burns JC, Newburger JW.
J Am Heart Assoc; 2016 Sep 15; 5(9):. PubMed ID: 27633390
[Abstract] [Full Text] [Related]
14. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.
Youn Y, Kim J, Hong YM, Sohn S.
Pediatr Infect Dis J; 2016 Apr 15; 35(4):457-9. PubMed ID: 26673981
[Abstract] [Full Text] [Related]
15. Predicting IVIG resistance in UK Kawasaki disease.
Davies S, Sutton N, Blackstock S, Gormley S, Hoggart CJ, Levin M, Herberg JA.
Arch Dis Child; 2015 Apr 15; 100(4):366-8. PubMed ID: 25670405
[Abstract] [Full Text] [Related]
16. Coronary artery status of patients with transient fever 24-36 h after first IVIG infusion did not differ from that seen in responsive patients.
Baek JS, Yu JJ, Kim MJ, You J, Jun HO, Kim YH, Ko JK.
Pediatr Rheumatol Online J; 2018 Dec 29; 16(1):83. PubMed ID: 30594188
[Abstract] [Full Text] [Related]
17. Variability in Response to Intravenous Immunoglobulin in the Treatment of Kawasaki Disease.
Downie ML, Manlhiot C, Latino GA, Collins TH, Chahal N, Yeung RS, McCrindle BW.
J Pediatr; 2016 Dec 29; 179():124-130.e1. PubMed ID: 27659027
[Abstract] [Full Text] [Related]
18. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
Lancet Child Adolesc Health; 2018 Dec 29; 2(12):855-862. PubMed ID: 30337183
[Abstract] [Full Text] [Related]
19. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
[Abstract] [Full Text] [Related]
20. Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin.
Matsuoka R, Furuno K, Nanishi E, Onoyama S, Nagata H, Yamamura K, Sugitani Y, Kuraoka A, Mizuno Y, Sagawa K, Honjo S, Hara T, Ohga S.
J Pediatr; 2020 Dec 17; 227():224-230.e3. PubMed ID: 32810506
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
